Item 9.01 Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired.
The audited financial statements of Oncoceutics as of and for the year ended
December 31, 2020, together with the notes thereto and the auditor's report
thereon, are attached hereto as Exhibit 99.1 and are incorporated herein by
reference. The consent of CohnReznick LLP, the independent auditor of
Oncoceutics, is attached hereto as Exhibit 23.1 to this Current Report on Form
8-K.
(b) Pro Forma Financial Information
The unaudited pro forma consolidated combined statement of operations for the
Company and Oncoceutics for the year ended December 31, 2020 that gives effect
to the acquisition of Oncoceutics is attached hereto as Exhibit 99.2 and is
incorporated herein by reference. The unaudited pro forma consolidated combined
balance sheet for the Company and Oncoceutics as of December 31, 2020 is not
presented as the Merger is already reflected in the consolidated balance sheet
for the Company as of March 31, 2021. The unaudited pro forma consolidated
combined statement of operations for the Company and Oncoceutics for the three
months ended March 31, 2021 is not presented as there is no material difference
between the pro forma amounts and the actual results.
(d) Exhibits
Exhibit No. Description
23.1 Consent of CohnReznick LLP, independent auditor.
99.1 Audited financial statements of Oncoceutics as of and for the year
ended December 31, 2020, together with the notes thereto and the
auditor's report thereon.
99.2 Unaudited pro forma consolidated combined statement of operations
for the Company and Oncoceutics for the year ended December 31,
2020.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
© Edgar Online, source Glimpses